Compare KB Financial Group, Inc. (KB) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Merck & Co., Inc. — how do they compare? KB Financial Group, Inc. trades at $115.25 (market cap $38.56B), while Merck & Co., Inc. trades at $124.51 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 8× KB Financial Group, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| KB | MRK | |
|---|---|---|
Market Cap | $38.56B | $307.25B |
Sector | Financials | Health |
52-Week High | $123.25 | $129.52 |
52-Week Low | $77.50 | $77.60 |
Dividend Yield | 2.72% | 2.73% |
Enterprise Value | — | $350.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $115.23, down 3.47% today, but maintains a bullish technical outlook with strong moving average signals. The company shows solid fundamental performance with a 27.82% net income margin and consistent earnings beats in recent quarters. Revenue growth has been steady, reaching $21.23T in 2025, while analyst sentiment is mixed with a 33.33% buy rating amid broader hold consensus. Recent news highlights diversification into non-banking segments, which now contribute 43% of earnings.
The stock presents a balanced outlook with upside from earnings growth and diversification efforts, but faces risks from volatile cash flows and macroeconomic pressures. Investors should weigh the attractive valuation metrics against execution risks in non-banking expansion. The current price near recent highs suggests cautious optimism is warranted.
Merck (MRK) trades at $126.02, down 1.16% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of -$1.28 beating expectations. Revenue grew to $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook for MRK is positive, supported by robust fundamentals and analyst consensus, but risks include patent expirations and regulatory challenges. With a consensus price target of $137.30 offering ~9% upside, the stock presents a compelling opportunity for growth investors, though volatility from macroeconomic factors warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
